This paper is marked retracted in the scholarly record (OpenAlex). Interpret its findings with caution.
RETRACTION: Ivermectin Synergizes Sorafenib in Hepatocellular Carcinoma via Targeting Multiple Oncogenic Pathways
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsParasitic Diseases Research and Treatment · Helminth infection and control · Parasites and Host Interactions
Lu H. Zhou L. Zuo H. Le W. Hu J. Zhang T. Li M. Yuan Y. “Ivermectin Synergizes Sorafenib in Hepatocellular Carcinoma via Targeting Multiple Oncogenic Pathways.” Pharmacology Research & Perspectives 10 no. 3 2022: e00954. https://doi.org/10.1002/prp2.954.
The above article, published online 14 May 2022 on Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the Editor‐in‐Chief Professor Jennifer Martin, the British Pharmacological Society and John Wiley and Sons Ltd. The retraction has been agreed after concerns were raised that the Corresponding Author was not personally involved in the submission process, did not sign the Open Access Agreement, and did not review or approve the final version of the manuscript prior to submission. Additionally, the investigation uncovered evidence of duplication of several images and figures from previously published articles. The authors state that the conclusions of the article are otherwise unaffected.